Female reproductive organ cancer
MONDO:0001416A primary or metastatic malignant neoplasm involving the female reproductive system. Representative examples include endometrial carcinoma, cervical carcinoma, ovarian carcinoma, uterine corpus leiomyosarcoma, adenosarcoma, malignant mixed mesodermal (mullerian) tumor, and gestational choriocarcinoma.
Also known as: cancer of female reproductive organ, female reproductive cancer, female reproductive organ cancer, gynecologic cancer, malignant female reproductive organ neoplasm, malignant female reproductive system neoplasm, malignant female reproductive system tumor, malignant female reproductive system tumour
4802 clinical trials for this condition and its sub-types, 245 tagged with Female reproductive organ cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Female reproductive organ cancer
-
Uterine cancer 96 trials · 1,264 incl. sub-types
7 sub-types
- Cervical cancer 576 trials · 700 incl. sub-types Sub-types →
- Endometrial cancer 458 trials · 650 incl. sub-types Sub-types →
- Uterine carcinoma 3 trials · 614 incl. sub-types Sub-types →
- Uterine corpus cancer 33 trials · 85 incl. sub-types Sub-types →
- Uterine carcinosarcoma 23 trials · 32 incl. sub-types Sub-types →
- Placenta cancer 0 trials · 1 incl. sub-types Sub-types →
- Uterine adnexa cancer 0 trials Sub-types →
-
Ovarian cancer 1,004 trials · 1,200 incl. sub-types
11 sub-types
- Malignant epithelial tumor of ovary 8 trials · 656 incl. sub-types Sub-types →
- Malignant non-epithelial tumor of ovary 1 trial · 9 incl. sub-types Sub-types →
- Familial ovarian cancer 1 trial · 8 incl. sub-types Sub-types →
- Ovarian neuroendocrine neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Ovarian sarcoma 0 trials · 2 incl. sub-types Sub-types →
- Malignant ovarian cyst 1 trial
- Ovarian Wilms tumor 0 trials
- Ovarian adenosarcoma 0 trials
- Ovarian endometrioid adenocarcinofibroma 0 trials
- Ovarian lymphoma 0 trials
- Ovarian malignant mesothelioma 0 trials
-
Fallopian tube cancer 298 trials · 408 incl. sub-types
4 sub-types
- Fallopian tube carcinoma 126 trials · 182 incl. sub-types Sub-types →
- Cancer of isthmus of fallopian tube 0 trials
- Fallopian tube adenosarcoma 0 trials
- Fallopian tube leiomyosarcoma 0 trials
-
Endometrioid adenocarcinoma 13 trials · 146 incl. sub-types
6 sub-types
- Ovarian endometrioid adenocarcinoma 78 trials Sub-types →
- Endometrial endometrioid adenocarcinoma 56 trials Sub-types →
- Fallopian tube endometrioid adenocarcinoma 30 trials
- Stage I endometrioid carcinoma 16 trials
- Stage II endometrioid carcinoma 2 trials
- Cervical endometrioid adenocarcinoma 0 trials Sub-types →
-
Vulva cancer 88 trials · 102 incl. sub-types
8 sub-types
- Vulvar carcinoma 24 trials · 45 incl. sub-types Sub-types →
- Vulvar melanoma 3 trials
- Clitoris cancer 0 trials Sub-types →
- Labia minora cancer 0 trials Sub-types →
- Labium majus cancer 0 trials Sub-types →
- Mixed germ cell tumor of vulva 0 trials
- Paraurethral gland cancer 0 trials Sub-types →
- Vulva sarcoma 0 trials Sub-types →
-
Vaginal cancer 53 trials · 60 incl. sub-types
5 sub-types
- Vaginal carcinoma 12 trials · 22 incl. sub-types Sub-types →
- Malignant vaginal mixed epithelial and mesenchymal neoplasm 0 trials Sub-types →
- Vagina sarcoma 0 trials Sub-types →
- Vaginal adenosarcoma 0 trials
- Vaginal germ cell malignant tumor 0 trials Sub-types →
-
Adenosarcoma 0 trials · 2 incl. sub-types
5 sub-types
- Cervical adenosarcoma 1 trial Sub-types →
- Uterine corpus adenosarcoma 1 trial
- Fallopian tube adenosarcoma 0 trials
- Ovarian adenosarcoma 0 trials
- Vaginal adenosarcoma 0 trials
-
Gestational choriocarcinoma 0 trials · 1 incl. sub-types
4 sub-types
- Placental choriocarcinoma 1 trial
- Fallopian tube gestational choriocarcinoma 0 trials
- Gestational ovarian choriocarcinoma 0 trials
- Uterine corpus choriocarcinoma 0 trials
-
Adenocarcinofibroma 0 trials
3 sub-types
- Ovarian endometrioid adenocarcinofibroma 0 trials
- Ovarian mucinous adenocarcinofibroma 0 trials
- Uterine corpus adenocarcinofibroma 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 1016 trials in this tab.
-
Custom-Built immune cells take aim at a notorious cancer mutation
Cure OngoingResearchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Can engineered immune cells outsmart Drug-Resistant ovarian cancer?
Cure OngoingThis phase 1 trial tests an experimental therapy called AB-1015 in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. AB-1015 uses a patient's own T cells, which are genetically engineered to recognize and…
Phase 1 • Sponsor: Arsenal Biosciences, Inc. • Aim: Cure
Last updated Sep 05, 2026 00:00 UTC
-
Could a single HPV shot slash cervical cancer in africa?
Vaccine OngoingThis study in Tanzania tests whether one dose of the HPV vaccine works as well as the standard two or three doses in girls aged 9-14. Cervical cancer is a major killer in East Africa, and reducing the number of shots could cut costs and make vaccination more accessible. The trial…
Phase 3 • Sponsor: London School of Hygiene and Tropical Medicine • Aim: Vaccine
Last updated Sep 10, 2026 00:00 UTC
-
Can a DNA vaccine train the immune system to hunt down HER3-Positive cancers?
Vaccine OngoingThis phase 1 trial tests an investigational DNA vaccine called pING-hHER3FL in people whose solid tumors have been surgically removed. The vaccine carries the genetic code for the HER3 protein, which is found on many cancer types, and aims to trigger a targeted immune response ag…
Phase 1 • Sponsor: Herbert Lyerly • Aim: Vaccine
Last updated Sep 04, 2026 00:00 UTC
-
Quantum-Powered vaccine takes on endometrial cancer
Vaccine By invitation onlyThis early-phase trial is testing a personalized vaccine made from each patient's unique cancer mutations. The vaccine is designed to train the immune system to attack the cancer. Forty people with high-risk or recurrent endometrial cancer will receive the vaccine along with stan…
Early phase 1 • Sponsor: Biogenea Pharmaceuticals Ltd. • Aim: Vaccine
Last updated Jun 27, 2026 08:09 UTC
-
Oral drug that targets two cancer drivers tested in first human study
Disease control By invitation onlyResearchers are testing an experimental oral drug called ND-003 in Chinese patients with advanced solid tumors that have worsened after standard treatment or have no standard options left. ND-003 blocks two proteins, NTRK and RET, that can drive cancer growth when altered. The ph…
Phase 1 • Sponsor: Shenzhen NewDEL Biotech, Co., Ltd • Aim: Disease control
Last updated Sep 21, 2026 14:00 UTC
-
New vaccine combo shows promise in ovarian cancer fight
Disease control OngoingThis study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRαDC) with an immunotherapy drug (pembrolizumab) to help the immune system attack cancer cells. The trial …
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Sep 21, 2026 14:00 UTC
-
New drug cocktail shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 14:00 UTC
-
Mitochondria-Targeting drug gamitrinib tested for first time in humans
Disease control PausedResearchers are running a first-in-human Phase 1 trial of gamitrinib, an experimental drug that targets mitochondria in cancer cells, in people with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goal is to find the highest dose people …
Phase 1 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 14:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 21, 2026 14:00 UTC
-
New antibody drug conjugate tested against advanced cancers
Disease control OngoingResearchers are running a first-in-human phase 1 study of TORL-4-500, an antibody drug conjugate, in adults with advanced solid tumors, including hepatocellular carcinoma. The study has two parts: one to find the highest safe dose and the recommended dose for later trials, and an…
Phase 1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Sep 21, 2026 14:00 UTC
-
Immunotherapy combo shows promise in preventing High-Risk uterine cancer return
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (with or without radiation) after surgery can help prevent high-risk endometrial cancer from coming back. About 990 participants who had surgery to remove their uterus and ovaries will r…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Double-Target immunotherapy added to standard care for aggressive cervical cancer
Disease control By invitation onlyResearchers are testing whether adding cadonilimab, an immunotherapy drug, to chemotherapy before and after standard chemoradiation can help women with high-risk, locally advanced cervical cancer. The trial enrolls 20 women who have not received prior treatment. Participants rece…
Sponsor: Hubei Cancer Hospital • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immune cells take on tough tumors in early trial
Disease control OngoingThis early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…
Phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cancer drug combo enters human testing
Disease control OngoingThis early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New Antibody-Drug conjugate shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …
Phase 1/2 • Sponsor: Klus Pharma Inc. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancer mutation in first human trial
Disease control OngoingThis study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …
Phase 1/2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase 1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug cocktail shows promise in early cancer trial
Disease control OngoingThis phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug BNT314 enters first human safety trial
Disease control OngoingThis study is the first time BNT314 is being tested in humans. It aims to see if the drug is safe for people with advanced solid tumors that have not responded to other treatments. About 41 participants will receive different doses to find the highest dose that is still safe and …
Phase 1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Targeted pill takes aim at rare cancer mutations
Disease control OngoingThis phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug targets Sugar-Coated proteins on cancer cells
Disease control OngoingResearchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…
Phase 1 • Sponsor: Phost'In Therapeutics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Could a daily aspirin boost ovarian cancer treatment?
Disease control PausedThis early-phase study is testing whether taking a daily 325 mg aspirin alongside standard chemotherapy can reduce immune-suppressing cells in ovarian, fallopian tube, or peritoneal tumors. About 100 women will take either aspirin or a placebo for up to 5 cycles of chemo. The goa…
Early phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New antibody aims to preserve immune checkpoint while fighting cancer
Disease control OngoingResearchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…
Phase 1/2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise in battling recurrent ovarian cancer
Disease control OngoingThis study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise for rare ovarian cancer
Disease control OngoingThis pilot phase II study tests whether the drugs fulvestrant and abemaciclib can help control low-grade serous ovarian cancer in women with advanced disease. Up to 18 participants will receive the drugs before and after surgery. The goal is to see how many patients achieve a par…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New CAR-T therapy targets Hard-to-Treat cancers
Disease control PausedThis early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and atta…
Phase 1 • Sponsor: Chongqing Precision Biotech Co., Ltd • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Dual-Action antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Immune-Boosting drug takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…
Phase 1 • Sponsor: Tizona Therapeutics, Inc • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New immune drug shows promise in early trial for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …
Phase 1/2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo shows promise for tough ovarian cancers
Disease control OngoingThis study tests whether adding an experimental drug (AZD1775) to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 women will be randomly assigned to receive eith…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for rare ovarian tumors: targeted drugs under study
Disease control OngoingThis phase 2 trial is testing several targeted drugs in people with rare types of ovarian cancer that have come back or not gone away. The drugs are chosen based on specific biomarkers in each patient's tumor. The goal is to see if these treatments can shrink or control the cance…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New drug combo shows promise for tough cancers
Disease control OngoingThis early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Could a hormonal IUD replace surgery for some uterine cancers?
Disease control OngoingThis study looks at whether a hormonal intrauterine device (IUD) alone or combined with the drug everolimus can treat precancerous changes or very early-stage endometrial cancer. About 100 women with these conditions will receive the IUD, and some will also take everolimus if the…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New Immune-Boosting drug GEN1042 tested in japanese cancer patients
Disease control OngoingThis early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Drug combo aims to starve and block cancer in early trial
Disease control OngoingThis early-phase trial tested two oral drugs, cediranib and selumetinib, in 19 people with advanced solid tumors (including melanoma) that had stopped responding to standard treatments. Cediranib works by cutting off blood supply to tumors, while selumetinib blocks a key growth s…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New hope for Hard-to-Treat ovarian cancer: Rina-S faces off against standard chemo in major trial
Disease control OngoingThis study tests a new drug called Rina-S against standard chemotherapy for people with ovarian cancer that has stopped responding to platinum-based treatments. About 530 participants will be randomly assigned to receive either Rina-S or one of four approved chemo drugs. The goal…
Phase 3 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could a malaria drug help fight cancer? early trial tests new combo
Disease control OngoingThis early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Personalized dosing of cancer drug pazopanib tested in early trial
Disease control OngoingThis phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug duo shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tested a combination of two drugs, cabozantinib and nivolumab, in 82 people with advanced, recurrent, or metastatic endometrial cancer. The goal was to see if the combo could slow or stop cancer growth. Cabozantinib blocks enzymes that help tumors grow, while nivolumab…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Targeted drug shows promise for Hard-to-Treat brain and bile duct cancers
Disease control OngoingThis study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo aims to outsmart Platinum-Resistant ovarian cancer
Disease control OngoingThis phase 2 trial tests whether adding an experimental drug called M6620 (berzosertib) to standard gemcitabine chemotherapy helps women with ovarian, fallopian tube, or primary peritoneal cancer that came back after platinum-based treatment. About 70 participants will receive ei…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug takes aim at ovarian cancers that resist platinum chemotherapy
Disease control OngoingResearchers are testing an experimental drug called IBI354 in people with ovarian, primary peritoneal, or fallopian tube cancer that has stopped responding to platinum-based chemotherapy. The trial compares IBI354 given alone with one of four standard chemotherapy drugs chosen by…
Phase 3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for advanced endometrial cancer: three-drug combos tested in major trial
Disease control OngoingThis study tested three different drug combinations in 349 people with advanced (stage III or IV) or recurrent endometrial cancer. The goal was to see which combination worked best at stopping the cancer from growing or spreading. Participants received either paclitaxel/carboplat…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill combo aims to tame Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Immunotherapy drug nivolumab tested against tough cervical cancers
Disease control OngoingThis phase II trial tests the drug nivolumab (Opdivo) in 26 women with cervical cancer that has persisted, returned, or spread despite prior treatment. Nivolumab is an immunotherapy that helps the body's immune cells recognize and attack cancer. The study measures how many patien…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a smartphone app help cancer patients kick the habit?
Disease control OngoingThis phase III trial tests whether a smartphone app called Quit2Heal can help cancer patients stop smoking better than the standard QuitGuide app. The study involves 427 adults with cancer who smoke and are interested in quitting. Participants use one of the two apps to get suppo…
Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Experimental combo targets Hard-to-Treat HER2 cancers
Disease control OngoingThis early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can a new drug target Hard-to-Treat kidney and ovarian cancers?
Disease control OngoingThis trial tests an experimental drug called DS-6000a (also known as R-DXd) in people with advanced renal cell carcinoma (kidney cancer) and ovarian tumors. The main goals are to find a safe dose, identify side effects, and see if the drug can shrink tumors. Participants receive …
Phase 1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo targets tumors in patients with organ failure
Disease control OngoingThis early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…
Phase 1/2 • Sponsor: ImCheck Therapeutics, an Ipsen company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Can fewer, stronger radiation doses spare the bowel in gynecologic cancers?
Disease control OngoingThis pilot study tests whether hypofractionated radiation therapy, which gives higher doses over fewer sessions, is a practical option for people with non-metastatic cervical or endometrial cancer after hysterectomy. Researchers will measure bowel and urinary side effects using p…
Sponsor: University of Utah • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat recurrent cancers
Disease control OngoingThis early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Personalized cancer attack: new trial matches drugs to tumor genes
Disease control OngoingThis phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo shows promise for hard-to-treat HER2 cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New hope for rare sarcomas: targeted pill attacks Cancer's DNA repair
Disease control OngoingThis study tests a drug called niraparib in people with advanced soft tissue sarcoma that has certain DNA repair gene changes. The goal is to see if the drug can stop or slow tumor growth. About 8 adults with inoperable or metastatic sarcoma will take niraparib pills and be monit…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can a radioactive drug seek out and attack solid tumors?
Disease control OngoingThis early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…
Phase 1 • Sponsor: Monopar Therapeutics • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …
Phase 1/2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThis early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New cancer drug saruparib enters early human testing
Disease control OngoingThis early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could cutting vitamin B6 boost cancer immunotherapy?
Disease control OngoingThis early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New liposome chemo shows promise in early cancer trial
Disease control OngoingThis early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new gemcitabine formulation outsmart advanced solid tumors?
Disease control OngoingThis phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a cocktail of immune boosters shrink Hard-to-Treat tumors?
Disease control OngoingThis phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
Disease control OngoingThis phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…
Phase 1/2 • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Precision drug shows promise for rare Gene-Driven cancers
Disease control OngoingThis study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for rare tumors: tarlatamab trial opens
Disease control OngoingThis study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Cancer drug brigimadlin tested for Long-Term use in solid tumour patients
Disease control OngoingThis study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug cocktail shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial is testing whether adding the targeted drug ipatasertib to standard chemotherapy (paclitaxel and carboplatin) is safe and effective for women with advanced ovarian cancer. The study involves 25 participants with stage III or IV disease. The goal is to find …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a smart drug deliver a One-Two punch to advanced cancers?
Disease control PausedThis trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …
Phase 1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug duo aims to shrink hard-to-treat tumors
Disease control OngoingThis early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New program helps cancer survivors fight heart disease with exercise
Disease control OngoingThis study tests a clinic program called ActivityChoice that helps cancer survivors become more physically active to lower their risk of heart disease. About 114 adult cancer survivors will be offered a choice of group in-person, group virtual, or self-monitored digital exercise …
Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Diet and exercise may keep cancer patients stronger during chemo
Disease control OngoingThis study tests whether early, personalized nutritional support and a simple home exercise program can prevent weight loss and improve quality of life in 200 adults with lung, colorectal, ovarian, or pancreatic cancer starting palliative chemotherapy. Participants receive guidan…
Sponsor: Gødstrup Hospital • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New cancer drug AB598 enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New triple therapy targets Hard-to-Treat cancers
Disease control OngoingThis study tests a combination of three drugs—bintrafusp alfa, PDS01ADC, and entinostat—in adults with advanced HPV-related cancers (like cervical, anal, or throat cancer) or certain colon cancers that haven't responded to standard treatment. The goal is to find a safe dose and s…
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New immunotherapy shows promise against multiple advanced cancers
Disease control OngoingThis study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New hope for advanced cervical cancer: MK-2870 trial launches
Disease control OngoingThis Phase 3 trial compares a new drug, MK-2870, against standard treatments for people with recurrent or metastatic cervical cancer that has progressed after initial therapy. About 686 participants will receive either MK-2870 or a doctor-chosen standard treatment. The main goal …
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Cancer drug safety tracked in ongoing rollover trial
Disease control By invitation onlyThis study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New drug cocktails show promise against tough endometrial cancer
Disease control OngoingThis study tests several drug combinations in women with endometrial cancer that has returned or not responded to treatment. The drugs work by blocking cancer cell growth or helping the immune system attack tumors. The goal is to see if these combinations can slow or stop the can…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New cocktail of drugs could offer hope for Hard-to-Treat ovarian cancer
Disease control OngoingThis study tests whether adding immunotherapy (atezolizumab) and/or a blood vessel blocker (bevacizumab) to standard chemo (pegylated liposomal doxorubicin) works better for ovarian cancer that has stopped responding to platinum drugs. About 444 women with recurrent ovarian, fall…
Phase 2/3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Could a simple shot replace IV drips for some cancer patients?
Disease control OngoingThis early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug takes on chemo in major trial
Disease control OngoingThis study tests a new drug, MK-2870, against standard chemotherapy in about 710 people with endometrial cancer that has worsened after platinum chemo and immunotherapy. The goal is to see if MK-2870 helps people live longer and delays cancer growth. Participants are randomly ass…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for rare ovarian cancer: which chemo combo works best?
Disease control OngoingThis phase 3 trial tests two different chemotherapy regimens, with or without the targeted drug bevacizumab, as first treatment for a rare type of ovarian or fallopian tube cancer called mucinous epithelial cancer. About 50 patients with newly diagnosed or recurrent cancer will b…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill may keep endometrial cancer at bay longer
Disease control OngoingThis study tests whether the drug selinexor can help keep advanced or recurrent endometrial cancer from growing back after initial chemotherapy. About 276 adults whose cancer has a normal p53 gene and who responded to platinum-based chemo will receive either selinexor or a placeb…
Phase 3 • Sponsor: Karyopharm Therapeutics Inc • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New liposomal drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…
Phase 1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Glowing dye could cut bowel leak risk in ovarian cancer surgery
Disease control OngoingThis study tests whether using a fluorescent dye and special camera during ovarian cancer surgery can help surgeons see blood flow in the bowel and reduce the risk of leaks after reconnecting it. About 310 women with ovarian cancer who need bowel surgery will be randomly assigned…
Phase 3 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Oral chemotherapy candidate utidelone moves to human testing for advanced cancers
Disease control OngoingThis early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …
Phase 1/2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
A nudge in the electronic chart may get ovarian cancer patients to specialists faster
Disease control By invitation onlyThis trial tests whether a small electronic reminder can help people with suspected ovarian cancer get referred to a gynecologic oncologist sooner. When imaging results suggest ovarian cancer, doctors will see a pre-checked referral order in the patient's chart, along with a brie…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New drug combo shows promise for recurrent ovarian cancer
Disease control OngoingThis phase II trial tests whether adding the immunotherapy tremelimumab to the PARP inhibitor olaparib works better than olaparib alone for women with platinum-sensitive recurrent ovarian, fallopian tube, or peritoneal cancer. About 61 participants will receive either olaparib al…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New pill takes on tough cancers in first human test
Disease control OngoingThis early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…
Phase 1 • Sponsor: Circle Pharma • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Cancer drug regorafenib gets a second chance in small continuation study
Disease control OngoingThis study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug dostarlimab shows promise in early trial for advanced cancers
Disease control OngoingThis early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…
Phase 1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug targets rare gene fusions in multiple cancers
Disease control OngoingThis phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a Dual-Action drug outsmart advanced cancers?
Disease control OngoingThis early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…
Phase 1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for aggressive uterine cancer: targeted drug trial shows promise
Disease control OngoingThis study tests an investigational drug called AZD1775 in women whose uterine cancer has come back or persists. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing tumor growth. About 49 participants with two aggressive types of ut…
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Measles virus hijacks stem cells to attack ovarian cancer
Disease control OngoingThis early-phase trial tests a new approach for recurrent ovarian, fallopian tube, or peritoneal cancer. Doctors take stem cells from the patient's fat tissue, infect them with a modified measles virus, and inject them into the abdomen. The idea is that the stem cells will delive…
Phase 1/2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Extended look at gotistobart: could Long-Term use improve survival in advanced cancers?
Disease control By invitation onlyThis extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …
Phase 3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…
Phase 1/2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
New hope for advanced cervical cancer: drug trial targets remaining risk
Disease control OngoingThis study tests an experimental drug called volrustomig in 37 women with high-risk, locally advanced cervical cancer that hasn't gotten worse after standard chemotherapy and radiation. The goal is to see if the drug can help keep the cancer from coming back or spreading. Partici…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 20, 2026 00:00 UTC
-
New cancer drug AB801 enters human safety testing
Disease control OngoingThis early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New study tackles obesity in endometrial cancer survivors
Disease control OngoingThis study helps early-stage endometrial cancer survivors with obesity start a weight management program and possibly take weight loss medications. Researchers want to see if referring patients to a weight loss clinic helps them begin treatment. The goal is to improve long-term h…
Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Cancer drug pertuzumab tested for Long-Term use in extension trial
Disease control OngoingThis study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Cancer patients who respond to drug get continued access in new study
Disease control By invitation onlyThis study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for endometrial cancer: immunotherapy and targeted drug combo tested
Disease control OngoingThis Phase 3 trial tests whether adding the immunotherapy drug durvalumab and the targeted therapy olaparib to standard chemotherapy can help women with newly diagnosed advanced or recurrent endometrial cancer live longer without their cancer growing. About 805 participants will …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
Disease control OngoingThis early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…
Phase 1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Triple-Drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Immunotherapy duo takes on cervical cancer in new trial
Disease control OngoingThis Phase 2 trial tests whether adding relatlimab to nivolumab (both immunotherapy drugs) works better than nivolumab alone for locally advanced cervical cancer. About 77 women with stage IIB to IVA cervical cancer will receive either the combination or nivolumab alone before st…
Phase 2 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New hope for endometrial cancer: targeted drug faces off against standard chemo
Disease control OngoingThis study tests a drug called sacituzumab govitecan against standard chemotherapy in 640 people with endometrial cancer that has come back after platinum-based chemo and immunotherapy. The goal is to see if the new drug can slow cancer growth and help people live longer. Partici…
Phase 3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
Disease control OngoingThis trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …
Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Cancer drug spartalizumab gets extended safety check in ongoing patients
Disease control OngoingThis study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled f…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer drug futibatinib gets a safety check in Long-Term rollover study
Disease control OngoingThis study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…
Phase 2/3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer patients get extended access to promising immunotherapy
Disease control OngoingThis study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing a…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Personalized weight loss coaching could help cancer survivors shed pounds
Disease control OngoingThis study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New hope for endometrial cancer: drug combo shows promise
Disease control OngoingThis study tests a combination of drugs (durvalumab, chemotherapy, and olaparib) as a first treatment for people with advanced or recurrent endometrial cancer that has a specific genetic marker (pMMR). The goal is to see how safe and tolerable the treatment is. About 85 people in…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a lighter immunotherapy schedule keep advanced cancers in check?
Disease control OngoingThis trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug cocktail shows promise for tough cancers
Disease control OngoingThis study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in japanese patients
Disease control OngoingThis study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…
Phase 1/2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Digital assistant aims to close gaps in hereditary cancer care
Disease control By invitation onlyThis trial tests a digital tool that helps doctors and patients manage cancer risks linked to hereditary syndromes like BRCA-related breast/ovarian cancer and Lynch syndrome. The tool provides personalized recommendations during primary care visits. Researchers compare care gaps,…
Sponsor: HealthPartners Institute • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New program aims to protect cancer Patients' hearts during treatment
Disease control By invitation onlyThis study looks at whether a special program called Primary Care Connect (PC2) helps cancer survivors who also have conditions like high blood pressure, diabetes, or high cholesterol keep their heart risks under control during cancer treatment. About 266 adults with early-stage …
Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug shows promise against multiple Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New immunotherapy targets tough pancreatic cancers in early trial
Disease control OngoingThis early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…
Phase 1/2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Cancer patients get continued access to lifesaving drug in new study
Disease control OngoingThis study offers continued treatment with the cancer drug osimertinib to patients who have already benefited from it in a previous trial. The goal is to keep providing the drug while monitoring safety and side effects. About 37 adults with cancer who are still doing well on the …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New cocktail aims to stall ovarian cancer
Disease control OngoingThis Phase 3 trial tests whether adding durvalumab (an immunotherapy) and olaparib (a targeted drug) to standard chemotherapy and bevacizumab can help people with newly diagnosed advanced ovarian cancer live longer without their cancer growing. About 1,400 participants are involv…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Cancer patients get continued access to key therapy in extension study
Disease control OngoingThis study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New cancer combo aims to shrink Hard-to-Treat tumors
Disease control OngoingThis study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Cancer drug safety tracked over years in ongoing study
Disease control OngoingThis study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingThis study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…
Phase 2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New hope: drug before surgery may shrink ovarian tumors
Disease control OngoingThis study tests whether the drug olaparib, given before surgery, can shrink tumors in women with recurrent ovarian cancer that has come back after at least 6 months. About 71 participants will receive either olaparib or standard chemotherapy before surgery. Researchers will meas…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to outsmart resistant cancers
Disease control OngoingThis early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Ovarian cancer combo shows promise in maintenance therapy
Disease control OngoingThis phase IV trial tests whether the drugs olaparib and bevacizumab, taken together after initial chemotherapy, can help prevent ovarian cancer from coming back in women with a specific genetic marker (HRD-positive). About 190 participants who have already responded to first-lin…
Phase 4 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New oral drug aims to tackle Hormone-Driven cancers
Disease control OngoingThis study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody drug takes on advanced tumors in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…
Phase 1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Immunotherapy after Chemo-Radiation shows promise for advanced cervical cancer
Disease control OngoingThis study tests whether the immunotherapy drug TSR-042 can help prevent cervical cancer from returning in patients with high-risk locally advanced disease who have completed standard chemo-radiation. About 134 women will receive TSR-042 as a maintenance therapy to see if it exte…
Phase 2 • Sponsor: Grupo Español de Investigación en Cáncer de Ovario • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Lifeline for cancer patients: continued access to promising drug olaparib
Disease control OngoingThis study offers continued treatment with the drug olaparib to people with ovarian or breast cancer who have already seen benefits from it in a previous study. The goal is to keep providing the drug safely while monitoring for any serious side effects. About 185 participants wil…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug cocktail targets Hard-to-Treat ovarian and uterine cancers
Disease control OngoingThis early-phase trial tests an investigational drug called RP-6306 alongside standard chemotherapy (carboplatin and paclitaxel) in 6 women with recurrent ovarian or uterine cancer that has a specific genetic change (TP53 mutation). The main goal is to find a safe dose and check …
Phase 1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug AZD9592 enters first human trials for tough cancers
Disease control OngoingThis early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Promising combo for Hard-to-Treat ovarian cancer never got off the ground
Disease control CancelledThis study was designed to test whether a new drug called M4344, combined with the PARP inhibitor niraparib, could be safe and effective for women with recurrent ovarian cancer that had stopped responding to PARP inhibitors. The plan was to enroll women with advanced ovarian, pri…
Phase 1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo shows promise against advanced cervical cancer in early trial
Disease control OngoingThis study tests whether adding a new immunotherapy drug (cadonilimab) to chemotherapy before the usual chemoradiation can shrink tumors better in people with locally advanced cervical cancer. About 29 participants will receive the combination, then standard treatment. The goal i…
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New robot could transform hysterectomy surgery
Disease control OngoingThis study is testing a new robotic system, the Medtronic Hugo™, for performing hysterectomies. It includes 70 patients with conditions like uterine fibroids, endometriosis, or certain cancers. The goal is to see if the robot is safe and can complete the surgery without switching…
Sponsor: Medtronic - MITG • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug cocktail aims to stall ovarian cancer recurrence
Disease control OngoingThis Phase 3 trial is testing whether adding mirvetuximab soravtansine (a drug that targets a protein called FRα on cancer cells) to standard bevacizumab maintenance therapy can delay cancer progression in women with recurrent ovarian, fallopian tube, or peritoneal cancer. The st…
Phase 3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Can simple tools help cancer survivors live healthier?
Disease control OngoingThis study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…
Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Fewer trips to the hospital? new cervical cancer radiation trial aims to cut treatment time
Disease control OngoingThis study compares a shorter, higher-dose radiation schedule (hypofractionated) to the standard longer schedule for cervical cancer patients also receiving chemotherapy. The goal is to see if the shorter schedule is just as safe and effective, while reducing the number of hospit…
Sponsor: Siriraj Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New cancer drug shows promise in early trial
Disease control OngoingThis early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Heated chemo during surgery may extend life in ovarian cancer relapse
Disease control OngoingThis study tests whether adding heated chemotherapy directly into the abdomen during surgery can help people with relapsed ovarian cancer live longer. About 415 adults whose cancer returned in the abdomen after initial treatment will take part. The approach aims to control the di…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug combo shows promise in shrinking cervical tumors before surgery
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug QL1706 to standard chemotherapy before hysterectomy can improve outcomes for people with locally advanced cervical cancer. About 54 participants will receive three cycles of the combination, then surgery if the tumor …
Phase 2 • Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Virus therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…
Phase 1 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New targeted therapy shows promise for Tough-to-Treat ovarian cancer
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in people with a specific type of recurrent ovarian cancer that has high levels of a protein called folate receptor alpha. The drug delivers chemotherapy directly to cancer cells to try to slow or stop the cancer from growi…
Phase 2 • Sponsor: AGO Research GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug duo aims to outsmart stubborn cancers
Disease control OngoingThis early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Drug combo shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …
Phase 1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy for endometrial cancer shows promise in early trial
Disease control OngoingThis early-phase trial is testing whether adding the immunotherapy drug pembrolizumab to standard radiation and chemotherapy is safe and feasible for people with high-intermediate risk endometrial cancer. About 45 participants who have already had surgery to remove the uterus wil…
Phase 1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
New gene therapy combo shows promise in ovarian cancer trial
Disease control OngoingThis study tests whether adding a gene therapy called IMNN-001 to standard chemotherapy can help people with advanced ovarian, fallopian tube, or peritoneal cancer live longer without their cancer growing. About 130 newly diagnosed patients will receive either the combination or …
Phase 1/2 • Sponsor: Imunon • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Virus therapy takes on Platinum-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new approach for ovarian cancer that has stopped responding to platinum chemotherapy. It combines TILT-123, a virus engineered to kill cancer cells and boost immune activity, with the immunotherapy drug pembrolizumab, and in some cases also with a c…
Phase 1/2 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Immunotherapy before surgery shows promise for aggressive uterine cancer
Disease control OngoingThis study tests whether giving the immunotherapy drug pembrolizumab before standard surgery can shrink tumors in people with a specific type of uterine cancer (MMRd). Twelve participants will receive 9 cycles of pembrolizumab before their hysterectomy. The goal is to see how man…
Phase 2 • Sponsor: University Medical Center Groningen • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Can a Nurse-Led program transform Women's health in hong kong?
Disease control OngoingThis trial tests a nurse-led health program for women aged 45 to 64 in Hong Kong. The program uses a 5-step approach (ask, advice, assess, assist, arrange) to help women manage conditions like high blood pressure, anxiety, and menopause symptoms. Researchers will compare the prog…
Sponsor: The University of Hong Kong • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Promising drug shrinks tumors in advanced cancers
Disease control OngoingThis study tested a drug called sacituzumab govitecan in 227 people whose solid tumors had spread to other parts of the body. The main goal was to see if the drug could shrink tumors. Researchers measured how many patients had their tumors shrink or disappear. This is not a cure,…
Phase 2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New combo therapy aims to boost immunotherapy in Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Cancer drug combo trial pulled before it even started
Disease control CancelledThis study was designed to test the safety and effectiveness of two drugs, bemarituzumab and bevacizumab, given together to people with advanced gynecologic cancers (endometrial, ovarian, or cervical) that have a specific protein called FGFR2b. The trial was withdrawn before enro…
Phase 1/2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody takes aim at Hard-to-Treat cancers
Disease control OngoingThis Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…
Phase 2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo tested for advanced cancers
Disease control OngoingThis early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill shows promise against Hard-to-Treat RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Cancer patients get continued access to promising drug
Disease control OngoingThis study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New hope for hard-to-treat ovarian cancer: drug duo enters phase 2 trial
Disease control OngoingThis study tests whether combining two immunotherapy drugs, ONC-392 and pembrolizumab, can shrink tumors in people with platinum-resistant ovarian cancer. About 58 adults with high-grade serous ovarian, primary peritoneal, or fallopian tube cancer are taking part. The goal is to …
Phase 2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Heated chemo during surgery may boost ovarian cancer survival
Disease control OngoingThis study tests whether adding heated chemotherapy directly into the abdomen during surgery helps people with stage III ovarian cancer live longer. About 538 participants will be randomly assigned to standard surgery alone or surgery plus the heated chemo. The main goal is to se…
Phase 3 • Sponsor: The Netherlands Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Ovarian cancer hope: new antibody combo aims to delay disease worsening
Disease control OngoingThis Phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps people with newly diagnosed advanced ovarian cancer live longer without their cancer getting worse. About 615 participants who had surger…
Phase 3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New device aims to prevent vaginal scarring after cancer radiation
Disease control By invitation onlyThis study tests a special device that combines a vaginal dilator with a drug delivery tube to help prevent vaginal narrowing and scarring after pelvic radiation therapy. About 76 women aged 18-70 who have completed radiation for pelvic tumors will use the device regularly. The g…
Sponsor: Peking Union Medical College Hospital • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Heated chemotherapy during surgery may delay ovarian cancer return
Disease control OngoingThis phase 3 trial tests whether giving heated chemotherapy directly into the abdomen during surgery can help people with advanced ovarian cancer live longer without the disease coming back. About 362 participants will either receive standard surgery alone or surgery plus the hea…
Phase 3 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New texting system aims to boost cervical cancer screening in kenya
Disease control OngoingThis study tests a web-based tool called the Cancer Tracking System (CATSystem) that sends automated texts and alerts to help women in Kenya get timely cervical cancer screening and follow-up care. About 6,600 women across 10 hospitals will take part, with half the hospitals usin…
Sponsor: University of Kansas Medical Center • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New hope for ovarian cancer: drug may delay return of disease
Disease control OngoingThis study tests whether the drug olaparib can help keep advanced ovarian cancer from coming back in people who do not have a BRCA gene mutation. Participants have already responded well to initial chemotherapy. The trial compares olaparib to a placebo to see if it extends the ti…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo therapy aims to delay ovarian cancer return
Disease control OngoingThis phase 2 trial tests whether a combination of three drugs—olaparib, durvalumab, and a cancer vaccine called UV1—can help keep ovarian cancer from coming back after chemotherapy. The study includes 188 patients with recurrent ovarian cancer who do not have BRCA mutations. Part…
Phase 2 • Sponsor: Nordic Society of Gynaecological Oncology - Clinical Trials Unit • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Gene-Guided drug cocktail shows promise for Tough-to-Treat gynaecological cancers
Disease control OngoingThis phase 2 trial tests a new drug (ceralasertib) alone or combined with either olaparib or durvalumab in 174 people whose gynaecological cancer has returned. The study groups patients by their cancer type and whether they have a change in the ARID1A gene. The goal is to see if …
Phase 2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New study aims to help cancer survivors manage other health problems
Disease control OngoingThis study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …
Sponsor: Duke University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Can a simple tube removal during hysterectomy slash ovarian cancer risk?
Disease control OngoingThis study looks at whether removing the fallopian tubes at the same time as a hysterectomy (for non-cancer reasons) can lower the chance of getting ovarian cancer later. About 4,400 women under 55 will be randomly assigned to have their tubes removed or not. Researchers will tra…
Sponsor: Göteborg University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Experimental cancer combo aims to supercharge immune attack on tumors
Disease control OngoingThis early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…
Phase 1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…
Phase 1 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Heated chemo during surgery may extend life for Drug-Resistant ovarian cancer
Disease control OngoingThis study tests whether a combination of surgery to remove visible tumors plus heated chemotherapy delivered directly into the abdomen can help people with ovarian cancer that has stopped responding to standard platinum-based chemo. About 140 adults with this type of recurrent o…
Phase 3 • Sponsor: National Cancer Center, Korea • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug duo aims to tackle returning cervical cancer
Disease control OngoingThis Phase 2 trial is testing whether combining two drugs, niraparib and dostarlimab, can help shrink or control cervical cancer that has come back or spread. About 66 women with recurrent or progressive cervical cancer will receive the treatment. The goal is to see how many resp…
Phase 2 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New pill targets aggressive tumors with genetic flaw
Disease control OngoingThis early-phase study tests an experimental oral drug (GSK4418959) in adults with advanced solid tumors that have specific genetic changes (dMMR or MSI-H). The drug works by blocking a protein (WRN) that these tumors need to survive. The study aims to see if the drug, alone or w…
Phase 1/2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New pill may keep ovarian cancer at bay after chemo
Disease control OngoingThis phase 3 study tests a drug called IMP4297 (a PARP inhibitor) as a maintenance treatment for people with advanced ovarian cancer (stage III or IV) who have finished their first round of chemotherapy. The goal is to see if taking this drug daily can delay the cancer from comin…
Phase 3 • Sponsor: Impact Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New targeted drug aims to fight hard-to-treat bladder cancers
Disease control OngoingThis study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…
Phase 1/2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
Supercharged immune cells take on advanced cancers
Disease control OngoingThis early-phase trial tests a new approach to treat advanced solid tumors by giving patients a large dose of their own immune cells that are specially selected to attack cancer. The cells are taken from the tumor, multiplied in the lab, and then infused back. Some patients also …
Phase 1 • Sponsor: AgonOx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New oral drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug shows promise for rare lung cancer subtype
Disease control OngoingThis phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…
Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug cocktail shows promise in battle against advanced ovarian cancer
Disease control OngoingThis study tests whether adding two newer drugs (dostarlimab and niraparib) to standard chemotherapy helps people with advanced ovarian cancer live longer without their cancer growing. About 1,400 participants with stage III or IV ovarian cancer will receive either the standard t…
Phase 3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New study challenges safety of keyhole surgery for cervical cancer
Disease control OngoingThis study compares two surgical methods for early-stage cervical cancer: minimally invasive (keyhole or robot-assisted) surgery and traditional open abdominal surgery. Researchers will follow 2000 patients for up to 5 years to see which approach leads to better survival and fewe…
Sponsor: Huazhong University of Science and Technology • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New drug cocktail targets tough ovarian cancer in japanese women
Disease control OngoingThis phase 2 study tests a combination of two drugs, avutometinib and defactinib, in 16 Japanese patients whose low-grade serous ovarian cancer has returned after platinum-based chemotherapy. The goal is to see if the combo can shrink tumors and how safe it is. The trial is activ…
Phase 2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New pill could keep ovarian cancer at bay for BRCA patients
Disease control OngoingThis phase 3 trial tests whether taking olaparib tablets daily can delay the return of advanced ovarian cancer in women with BRCA gene mutations. Participants had already responded to initial platinum chemotherapy. The study compares olaparib to a placebo over up to two years, me…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Immunotherapy drug dostarlimab takes on chemo in advanced endometrial cancer trial
Disease control OngoingThis phase 3 trial compares the immunotherapy drug dostarlimab with standard chemotherapy in 260 women with advanced or recurrent endometrial cancer that has a specific DNA repair defect (MMR deficient). The goal is to see if dostarlimab can better delay cancer progression and im…
Phase 3 • Sponsor: ARCAGY/ GINECO GROUP • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called GH2616 in about 126 people with advanced solid tumors that have not responded to other treatments. The drug works by blocking a protein (KIF18A) that helps cancer cells divide, which may slow or stop tumor growth. The main goals are …
Phase 1 • Sponsor: Suzhou Genhouse Bio Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Ovarian cancer vaccine trial aims to keep tumors at bay
Disease control OngoingThis study tests a personalized immunotherapy called Vigil in 92 women with advanced ovarian cancer who are currently cancer-free after surgery and chemotherapy. The treatment uses the patient's own tumor cells to create a vaccine that trains the immune system to fight any remain…
Phase 2 • Sponsor: Gradalis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
When is the best time for ovarian cancer surgery?
Disease control OngoingThis study looks at the best time to perform surgery for advanced ovarian cancer. It compares having surgery right away versus after a few rounds of chemotherapy. The goal is to see which approach helps people live longer. About 800 women with stage IIIB-IV ovarian cancer are tak…
Sponsor: AGO Study Group • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
One-Visit HPV test and treatment could slash cervical cancer in poorer nations
Disease control OngoingThis study is testing whether it's practical and acceptable to offer HPV testing and immediate treatment for precancerous cervical lesions in the same visit. It involves over 17,600 women in Burkina Faso, Côte d'Ivoire, Guatemala, and the Philippines. The goal is to see if this i…
Sponsor: Jhpiego • Aim: Disease control
Last updated Jun 26, 2026 18:00 UTC
-
Can digital nutrition help cancer patients fight malnutrition?
Disease control OngoingThis study tests whether improved nutritional support, delivered through digital tools and personalized advice, can reduce malnutrition in cancer patients. Around 130 adults with gynecologic, colorectal, or lymphoma cancers will receive either standard dietary advice or enhanced …
Sponsor: University of Oslo • Aim: Disease control
Last updated Jun 26, 2026 14:40 UTC
-
Immunotherapy plus chemo shows promise in advanced uterine cancer trial
Disease control OngoingThis phase 3 study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy (carboplatin and paclitaxel) helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 785 participants receive either dostarlimab …
Phase 3 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Jun 26, 2026 12:51 UTC
-
Self-sampling for cervical cancer screening could make testing easier and more accessible
Diagnosis OngoingThis study tests whether offering a self-sampling HPV test at a clinic increases the number of women who get screened for cervical cancer. Women who are due for screening can choose between a self-sampled test, a clinician-sampled test, or no screening. The study measures how man…
Sponsor: Milton S. Hershey Medical Center • Aim: Diagnosis
Last updated Sep 20, 2026 00:00 UTC
-
New radioactive tracer could spot hidden tumors
Diagnosis OngoingThis early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …
Phase 1 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Sep 16, 2026 00:00 UTC
-
A new imaging agent aims to make solid tumors visible on PET scans
Diagnosis Expanded access (paused)This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…
Sponsor: Monopar Therapeutics • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
Can a radioactive antibody light up hidden tumors on PET scans?
Diagnosis OngoingResearchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…
Phase 1 • Sponsor: Monopar Therapeutics • Aim: Diagnosis
Last updated Sep 05, 2026 00:00 UTC
-
New PET tracer could spot ovarian cancer more clearly
Diagnosis OngoingThis early-phase study is testing a new radioactive tracer called [18F]FTT to see how it moves through the body and how well it lights up ovarian, fallopian tube, or peritoneal cancer on PET scans. Up to 40 women with known or suspected cancer will join two imaging groups. The go…
Phase 1 • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Diagnosis
Last updated Sep 04, 2026 00:00 UTC
-
New study aims to find the best way to catch HPV cancers early in HIV patients
Diagnosis OngoingThis study looks at which tests work best to find early signs of HPV-related cancer in the cervix or anus of people living with HIV. About 1,586 participants from Mexico and Puerto Rico will be tested using different methods, including HPV tests and cell samples. The goal is to c…
Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Aug 26, 2026 00:00 UTC
-
Can new tracers make many cancers light up on scans?
Diagnosis OngoingThis early-phase trial explores whether two experimental PET/CT tracers, 68Ga-FAPI-46 and 68Ga-PSMA-11, can accurately highlight various non-prostate cancers, including breast, lung, and pancreatic tumors. Participants scheduled for surgery will receive the tracers before their s…
Early phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Aug 23, 2026 00:00 UTC
-
AI that reads faces could spot hidden distress in cancer patients
Diagnosis By invitation onlyThis trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can a new PET tracer spot tumors more clearly?
Diagnosis CancelledThis trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…
Sponsor: Jinling Hospital, China • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Blood test may sharpen endometrial cancer risk prediction
Diagnosis OngoingThis study is testing whether a simple blood test can improve how doctors predict the risk of endometrial cancer returning after surgery. The test looks for tiny bits of tumor DNA and proteins in the blood before and after surgery. By combining this information with the current s…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
Finger-Prick test could replace needles for cancer blood monitoring
Diagnosis PausedThis study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …
Sponsor: Entia Ltd • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
New study aims to improve cervical cancer detection in HIV-Positive women
Diagnosis OngoingThis study compares different HPV tests to find the best way to screen for cervical cancer in women living with HIV in Latin America. Over 1,000 participants will provide cervical, vaginal, and urine samples, plus undergo colposcopy and biopsies. The goal is to identify which tes…
Sponsor: Weill Medical College of Cornell University • Aim: Diagnosis
Last updated Jun 28, 2026 00:00 UTC
-
AI could help ultrasound spot ovarian cancer earlier
Diagnosis OngoingThis study is testing whether artificial intelligence can help ultrasound scans better detect ovarian cancer in postmenopausal women. About 100 women with certain types of ovarian cysts will have their ultrasound images analyzed by AI. The goal is to see if the AI can match or be…
Sponsor: IRCCS Azienda Ospedaliero-Universitaria di Bologna • Aim: Diagnosis
Last updated Jun 27, 2026 14:01 UTC
-
Could a DIY swab replace the pelvic exam for cervical cancer screening?
Diagnosis OngoingThis study tests whether women can collect their own vaginal samples for HPV testing as accurately as a doctor's sample. It involves 750 women referred for colposcopy or cervical procedures. The goal is to see if self-collection is a reliable alternative to traditional pelvic exa…
Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Jun 27, 2026 14:00 UTC
-
Ovarian cancer recurrence detection study pulled before starting
Diagnosis CancelledThis study was designed to see if a blood test called the ROMA score could find ovarian cancer coming back sooner than the usual CA125 test. The goal was to catch recurrences early, which might allow less invasive surgery and improve quality of life. However, the study was withdr…
Sponsor: University Hospital, Tours • Aim: Diagnosis
Last updated Jun 27, 2026 13:07 UTC
-
Could a routine blood test spot many cancers early?
Diagnosis OngoingThis study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…
Sponsor: Zhejiang Cancer Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Hidden heart risk in cancer patients: simple ECG screening could save lives
Diagnosis OngoingThis study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…
Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
Spit test could spot ovarian cancer earlier
Diagnosis OngoingThis study looks at whether RNA in saliva can help tell the difference between ovarian cancer, borderline tumors, and benign cysts. Researchers are collecting saliva samples from 746 women before and after surgery. The goal is to find a simple, non-invasive way to speed up diagno…
Sponsor: ZIWIG • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
Can a simple HPV test replace colposcopy for cervical cancer Follow-Up?
Diagnosis OngoingThis study compares two ways to check for returning cervical pre-cancer after treatment: the standard colposcopy exam versus a high-risk HPV DNA test. Over 2,200 women who were treated for high-grade cervical lesions will be randomly assigned to one of the two follow-up methods. …
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Diagnosis
Last updated Jun 27, 2026 11:03 UTC
-
Simple blood test could transform cancer monitoring
Diagnosis OngoingThis study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…
Sponsor: University Hospital, Basel, Switzerland • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
New PET tracer could spot hidden cancers
Diagnosis OngoingThis early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
Can acupuncture detect hidden viruses in cervical cancer?
Diagnosis By invitation onlyThis study explores whether a non-invasive electroacupuncture technique can detect signs of persistent viruses, like HPV and SARS-CoV-2, in 30 women with advanced cervical cancer. Researchers will measure electrical responses at specific body points to see if they match viral pre…
Sponsor: Oncology Center,Ministry Of Heath,Uzbekistan • Aim: Diagnosis
Last updated Jun 27, 2026 08:09 UTC
-
Could mailing HPV tests boost screening rates?
Diagnosis OngoingThis study looks at whether offering HPV self-sampling kits by mail, pharmacy, or clinic can make cervical cancer screening easier. One thousand women aged 25-65 in Quebec will try different ways to get and return the kit. The goal is to see which method works best and if women f…
Sponsor: Université de Sherbrooke • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New Ultrasound-Guided biopsy could prevent dangerous surgery for uterine tumors
Diagnosis OngoingThis study looks at whether a special biopsy done with ultrasound guidance before surgery can correctly tell if a uterine tumor is cancerous or not. It involves 19 women aged 35 and older who have suspicious uterine tumors. The goal is to avoid risky surgical procedures if the tu…
Sponsor: Institut Bergonié • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
One shot to stop cancer: HPV vaccine study could change global prevention
Prevention OngoingThis study tests whether a single dose of the HPV vaccine can protect young women aged 18-30 from cervical cancer. Researchers in Costa Rica are giving 5,000 women either one HPV shot or a placebo to see if one dose is enough to prevent persistent HPV infections that can lead to …
Phase 4 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Sep 21, 2026 14:00 UTC
-
Can more phone calls after cancer surgery keep patients out of the hospital?
Prevention OngoingResearchers are testing whether a more intensive follow-up plan after major cancer surgery can reduce emergency room visits, hospital readmissions, and deaths within 30 days. Patients in the intervention group receive scheduled nurse video visits, check-ins with a medical provide…
Phase 3 • Sponsor: Fox Chase Cancer Center • Aim: Prevention
Last updated Sep 21, 2026 14:00 UTC
-
Can a smaller dose of a white blood cell booster protect cancer patients just as well?
Prevention By invitation onlyResearchers are studying whether a lower 3mg dose of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) can prevent febrile neutropenia, a serious drop in infection-fighting white blood cells, in cancer patients after chemotherapy. The standard 6mg do…
Sponsor: Zhejiang Provincial People's Hospital • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Aspirin shows promise in blocking ovarian cancer for High-Risk women
Prevention OngoingThis study tests whether taking aspirin can prevent ovarian cancer in women with BRCA1 or BRCA2 gene mutations, who are at high risk. About 117 participants will take either aspirin or a placebo daily for up to 2 years before their scheduled risk-reducing surgery. Researchers wil…
Phase 2 • Sponsor: Canadian Cancer Trials Group • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Can diet and exercise programs cut cancer risk? new study tests lifestyle changes
Prevention OngoingThis study tests different programs to help people at high risk for cancer (such as those with BRCA or Lynch syndrome) or cancer survivors increase their physical activity and eat healthier. The goal is to see which programs work best to reduce cancer risk. About 337 participants…
Sponsor: M.D. Anderson Cancer Center • Aim: Prevention
Last updated Sep 18, 2026 00:00 UTC
-
Can reminders and education prevent cervical cancer? a new trial aims to find out.
Prevention OngoingThis trial tests whether a program that combines educational materials with electronic health record reminders can increase HPV vaccination rates among children and young adults aged 11–26 in four Appalachian states. The goal is to improve vaccine uptake and ultimately prevent ce…
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Heart shield: diabetes drug may prevent Chemo-Induced cardiac damage
Prevention OngoingThis study tests whether empagliflozin, a drug used for diabetes, can prevent heart damage in cancer patients receiving strong chemotherapy (anthracyclines). About 220 adults with cancer but no prior heart failure will take either the drug or a placebo daily for 12 months. The go…
Phase 3 • Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Could a simple HPV test every 5 years replace frequent pap smears?
Prevention OngoingThis study compares two ways to screen for cervical cancer: a Pap smear every 2.5 years versus an HPV test every 5 years. Over 76,000 women aged 25-69 in Australia are taking part, including those who received the HPV vaccine and those who did not. The goal is to see if the less …
Sponsor: VCS Foundation • Aim: Prevention
Last updated Jun 27, 2026 12:09 UTC
-
At-Home test boosts cervical cancer screening in underscreened women
Prevention OngoingThis study looks at whether giving women a free self-sampling device (SSD) through their general practitioner (GP) can increase cervical cancer screening rates among those who haven't had a smear test in 6 years. About 3,375 women aged 31-64 in Flanders will be randomly assigned …
Sponsor: University Ghent • Aim: Prevention
Last updated Jun 27, 2026 09:06 UTC
-
New community effort aims to slash HPV risk in nigerian families
Prevention OngoingThis study tests a community-driven campaign to increase HPV prevention among mother-daughter pairs in Nigeria. About 1,838 participants will take part in events and surveys. The goal is to get more girls vaccinated against HPV and more mothers to self-test for the virus, which c…
Sponsor: Washington University School of Medicine • Aim: Prevention
Last updated Jun 27, 2026 09:01 UTC
-
One-Shot wonder? huge study tests single HPV vaccine dose
Prevention OngoingThis large study of nearly 28,000 girls aged 12-16 tests whether a single dose of HPV vaccine works as well as the standard two doses to prevent persistent infection with the virus types that cause most cervical cancers. If one dose is enough, it could lower costs and simplify va…
Phase 4 • Sponsor: National Cancer Institute (NCI) • Aim: Prevention
Last updated Jun 26, 2026 14:06 UTC
-
Hypnosis may calm cancer patients during radiation
Symptom relief OngoingThis study looks at whether medical hypnosis can help reduce anxiety in people with solid tumors who are getting radiation therapy. About 45 moderately to very anxious patients will either listen to relaxing music alone or combine it with hypnosis during their sessions. The goal …
Phase 2 • Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Sep 21, 2026 14:00 UTC
-
Phone therapy shows promise for depression in ovarian cancer patients
Symptom relief OngoingThis study looks at whether weekly phone counseling can help identify and treat depression in women with ovarian, peritoneal, or fallopian tube cancer. About 409 participants will either receive phone counseling or standard care with resource lists. The goal is to see which appro…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Home workouts may help endometrial cancer survivors shed pounds
Symptom relief OngoingThis study tests whether a home-based weight loss program, with or without resistance training, is practical for endometrial cancer survivors. Fifteen participants will follow a program using a workbook, fitness tracker, and coaching calls. The goal is to see if they can lose wei…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
One shot of radiation may ease cancer symptoms as well as multiple sessions
Symptom relief OngoingThis study compares a single session of palliative radiation therapy to the standard multiple sessions for people with gynecologic cancers that have spread. The goal is to see if one treatment can improve symptoms like pain and bleeding and boost quality of life just as well. Abo…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Mind over scalpel: Self-Hypnosis may ease Post-Surgery pain for cancer patients
Symptom relief OngoingThis study looks at whether listening to a self-hypnosis audio before surgery can help women with gynecologic cancer feel less pain and recover faster. About 152 patients having surgery for cancers of the female reproductive system will be randomly assigned to either usual care o…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can mindfulness ease cancer stress for latino families?
Symptom relief OngoingThis study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
New meditation program aims to ease cancer symptoms in black patients
Symptom relief OngoingThis study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Could a social media app help heal the emotional scars of cancer?
Symptom relief By invitation onlyThis trial tests whether a program designed to boost social connections can improve the social and emotional well-being of young adults who had cancer. Participants, aged 22-39 and diagnosed between 15-39, will receive a video and planning tools to encourage more in-person intera…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New program aims to reduce shame from chronic illness
Symptom relief OngoingThis study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…
Sponsor: University of Florida • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Needle in the spine: new hope for cancer pain?
Symptom relief OngoingThis study tests a procedure called cordotomy, where a needle is guided into the spinal cord to block pain signals. It's for people with advanced cancer who have severe pain on one side of the body below the shoulder. The goal is to see if it reduces pain better than a fake proce…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Nurses bring therapy to homebound cancer patients
Symptom relief OngoingThis study trains home-care nurses to deliver a short, meaning-centered psychotherapy to cancer patients who are homebound. The goal is to see if this approach can reduce psychological distress and improve quality of life. The trial involves 81 participants and focuses on trainin…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Pre-surgery fitness program tested in elderly cancer patients
Symptom relief OngoingThis study tests a program of exercise, protein drinks, and mind-body activities like yoga for people aged 65 and older with advanced ovarian or pancreatic cancer. The goal is to see if patients can stick with the program while on chemotherapy before surgery. The study is small, …
Phase 1/2 • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Can a common antipsychotic combo calm delirium in dying cancer patients?
Symptom relief OngoingThis study tests whether giving haloperidol alone or with chlorpromazine can safely calm severe agitation and confusion (delirium) in 70 advanced cancer patients in a palliative care unit. The main goal is to see if the drugs improve sedation scores within 24 hours. It is a phase…
Phase 2/3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can a virtual stress program help working spouses care for cancer patients without burning out?
Symptom relief OngoingResearchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…
Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Marijuana vs. opioids: which do cancer patients prefer for pain?
Symptom relief OngoingThis study looks at how cancer patients feel about using marijuana products (THC or CBD) compared to opioids for pain relief. Researchers will survey 200 adults with cancer-related pain who are already taking strong opioids. The goal is to understand patient preferences and perce…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Could fewer radiation sessions be safer for endometrial cancer?
Symptom relief PausedThis study is testing whether a shorter course of pelvic radiation (called hypofractionation) is safe for women with endometrial cancer. The researchers will find the best dose and see if it reduces bowel and urinary side effects. About 100 women who have already had surgery will…
Phase 1/2 • Sponsor: University of Chicago • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Can a text message help depressed cancer survivors get the care they need?
Symptom relief OngoingDepression is common among cancer survivors, but many don't get help. This pilot study tests a text-based referral platform that sends tailored messages and a video to encourage survivors to take up a mental health referral. The study will enroll 60 cancer survivors with depressi…
Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a Five-Session program help young cancer patients keep their friendships?
Symptom relief OngoingResearchers are testing a five-session program called PRISM-SN for people aged 12 to 25 who were recently diagnosed with cancer and are receiving chemotherapy or radiation. The program teaches skills for managing stress, setting goals, reframing negative thoughts, finding meaning…
Sponsor: Seattle Children's Hospital • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Poetry therapy aims to bring purpose to LGBTQ+ cancer patients at end of life
Symptom relief OngoingThis study tests a type of talk therapy called dignity therapy, adapted for sexual and gender minority (LGBTQ+) cancer patients. A trained researcher will interview participants about their lives and create a poem or legacy document they can share with loved ones. The goal is to …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
New program aims to restore intimacy after cancer radiation
Symptom relief PausedThis study tests a program that combines pelvic floor physical therapy with coping skills training to help women who have had pelvic radiation for cancer. The goal is to improve sexual function and quality of life. The study involves 12 cancer survivors and focuses on whether the…
Sponsor: Duke University • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Money worries in cancer care: new program aims to keep patients on track
Symptom relief OngoingThis study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Which meditation works best for cancer survivors? a new study aims to find out
Symptom relief PausedThis pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New digital coaching aims to ease cancer pain and cut opioid risks
Symptom relief OngoingThis study tests a program called ASCENT that helps cancer survivors manage pain using an educational guide and coaching from community health workers and pain care managers. The goal is to improve pain control and lower the risk of opioid misuse. About 660 adults with cancer-rel…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Sniffing lavender may ease biopsy pain and anxiety
Symptom relief PausedThis study tests whether inhaling lavender aromatherapy oil can reduce anxiety and pain for cancer patients undergoing a bone marrow biopsy. About 45 adults with cancer will be asked to use the oil during the procedure. The goal is to see if this simple, drug-free approach is som…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
New coaching program aims to help young cancer survivors connect with friends
Symptom relief OngoingThis study tests a communication coaching program for adolescent and young adult cancer survivors (ages 18-35) who have finished treatment at least a year ago. Participants complete online sessions and AI coaching to improve how they talk with peers. The goal is to see if the pro…
Sponsor: Milton S. Hershey Medical Center • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Exercise coaching may ease fatigue during radiation for endometrial cancer
Symptom relief OngoingThis study tests whether a personalized activity coaching program can help women feel less tired during pelvic radiation therapy for endometrial cancer. Sixteen participants will be randomly assigned to receive coaching or usual care. The main goal is to see if the program is pra…
Sponsor: Inova Health Care Services • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Could neck adjustments relieve Cancer-Related fatigue?
Symptom relief CancelledThis trial tests whether six weeks of upper cervical chiropractic care can help adults who have finished cancer treatment but still struggle with chronic fatigue. The study focuses on whether such a trial is practical, looking at recruitment, adherence, and acceptability. Partici…
Sponsor: Life University • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
Virtual yoga and dance therapy tested to fight cancer fatigue
Symptom relief OngoingThis study is testing whether a 12-week virtual program of mind-body classes (like yoga, dance therapy, and tai chi) can reduce fatigue and improve quality of life for people with head and neck, thoracic, gynecologic, or other cancers. About 480 adults currently receiving cancer …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 28, 2026 00:00 UTC
-
New program aims to ease pain for kids battling cancer
Symptom relief OngoingThis study tests a program called TIPPI-R that teaches children with cancer and their families ways to manage pain and distress during treatment. About 100 children aged 0-18 will either receive the program or standard care. Researchers will compare how well they cope with pain a…
Sponsor: University of Louisville • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
New online program aims to ease pain for cancer survivors
Symptom relief OngoingThis study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Virtual reality headsets may calm cancer patients before radiation
Symptom relief By invitation onlyThis trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…
Sponsor: Oman Ministry of Health • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
A digital bridge: could an online pathway ease depression in cancer care?
Symptom relief OngoingThis study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Mind over body: new film series aims to boost wellbeing in young cancer survivors
Symptom relief OngoingThis study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …
Sponsor: King's College London • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Community health workers step in to boost palliative care for black cancer patients
Symptom relief By invitation onlyThis study tests whether adding a trained community health worker (CHW) to standard care can improve quality of life and advance care planning for African American patients with advanced cancer. 160 patients will either receive standard care or standard care plus CHW support. The…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Faith and mindfulness join forces to heal black cancer survivors
Symptom relief By invitation onlyThis trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Can a smartphone app ease cancer Survivors' stress? new trial aims to find out
Symptom relief OngoingThis study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …
Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Testosterone gel trial aims to beat cancer fatigue in older men
Symptom relief OngoingThis study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…
Phase 2 • Sponsor: Seattle Institute for Biomedical and Clinical Research • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Green tea extract tested to fight frailty in older cancer survivors
Symptom relief PausedThis phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…
Phase 2 • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Money worries in cancer care: new study tests financial coaching to ease the burden
Symptom relief OngoingThis study tests whether a financial navigation and counseling program (CostCOM) can help newly diagnosed cancer patients who are struggling with costs or basic needs like food and housing. About 91 patients will either get the program, educational materials, or usual care. The g…
Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Cancer survivors find hope in Peer-Led Self-Management program
Symptom relief OngoingThis study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …
Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
New telehealth program aims to ease emotional burden of advanced cancer
Symptom relief By invitation onlyThis study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…
Sponsor: Ponce Medical School Foundation, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
No more hospital trips? video nutrition counseling tested for cancer weight loss
Symptom relief OngoingThis study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…
Sponsor: King Edward Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can exercising at home match gym sessions for cancer recovery?
Symptom relief OngoingThis study compares a 12-week digital home-based resistance exercise program to a supervised on-site program for cancer survivors who finished treatment up to 5 years ago. The main goal is to see which approach leads to better exercise adherence. Researchers will also measure eff…
Sponsor: Inland Norway University of Applied Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Holy Qur'an or music: which helps kids on chemo sleep better?
Symptom relief OngoingThis study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…
Sponsor: Rawand Shafeeq Ali • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Magic mushroom compound tested for Cancer-Related depression
Symptom relief OngoingThis study tests whether up to two doses of psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults who have both cancer and major depressive disorder. About 56 participants will receive either psilocybin or a placebo in a first session, and t…
Phase 2 • Sponsor: Sunstone Medical • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
SISTER study: peer support may boost cancer treatment completion
Symptom relief OngoingThis study tests whether group or one-on-one peer support helps Black patients with endometrial cancer complete their treatment and feel less isolated. About 252 participants will be randomly assigned to group support, one-on-one peer calls, or usual care. The main goal is to see…
Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Remote exercise and education program aims to boost Well-Being in older cancer patients
Symptom relief OngoingThis study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …
Sponsor: Martine Puts • Aim: Symptom relief
Last updated Jun 27, 2026 12:24 UTC
-
Can a short talk therapy beat insomnia in cancer patients?
Symptom relief OngoingThis study tests whether a brief behavioral therapy (BBT-CI) or a healthy eating education program (HEAL) works better for reducing insomnia in cancer patients. About 400 adults with stage I-IV cancer who are currently receiving treatment and have sleep problems will take part. T…
Phase 3 • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Exercise may soothe chemo nerve pain, trial hopes
Symptom relief OngoingThis study tests whether a structured exercise program can reduce chemotherapy-induced peripheral neuropathy (CIPN) — nerve damage causing pain, numbness, or tingling. About 133 cancer patients who received certain chemotherapies will either follow an exercise plan or receive sta…
Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Smartphone app aims to ease suffering for advanced cancer patients
Symptom relief OngoingThis study tests whether a mobile app called SUPPORT+ can improve quality of life for adults with advanced cancer who are no longer receiving anticancer treatment. Participants use the app to report symptoms weekly, get self-care tips, and receive nurse follow-up if symptoms are …
Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Spine adjustments tested as fatigue fix for cancer survivors
Symptom relief PausedThis pilot study explores whether chiropractic adjustments to the upper neck can reduce chronic fatigue in adults who have finished cancer treatment. About 40 cancer survivors who are currently cancer-free will receive either immediate or delayed chiropractic care for 6 to 12 wee…
Sponsor: Life University • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Cash for cancer care: $1,000 a month trial aims to ease financial burden
Symptom relief OngoingThis study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…
Sponsor: Meredith Doherty, PhD, LCSW • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Could a simple referral to palliative care ease End-of-Life suffering for cancer patients?
Symptom relief OngoingThis study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…
Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Could early palliative care before cancer surgery improve quality of life?
Symptom relief OngoingThis study looks at whether adding a palliative care team early, before surgery, helps cancer patients manage symptoms like pain, fatigue, and anxiety. About 236 adults having certain abdominal cancer surgeries will either get usual care or usual care plus palliative support. The…
Sponsor: Vanderbilt University Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Can acupuncture with electricity ease cancer brain fog and fatigue?
Symptom relief OngoingThis study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…
Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Texts and trackers: new study aims to get young cancer survivors moving
Symptom relief OngoingThis study tests whether a mobile health program can help adolescents and young adults (ages 15-39) who finished cancer treatment become more physically active. Participants get a personalized activity plan, a fitness tracker, access to an online survivor community, and motivatio…
Sponsor: AHS Cancer Control Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Can a smartphone app boost quality of life for young cancer patients?
Symptom relief OngoingThis study tests whether a phone app called OnKO-Tips&Tricks can improve the quality of life for adolescents and young adults (ages 15-25) recently diagnosed with cancer. The app helps with daily check-ins, education, and connecting with a nurse coordinator. Researchers will comp…
Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Forest bathing tested as fatigue fix for cancer survivors
Symptom relief By invitation onlyThis study tests whether nature-based therapies can reduce fatigue and improve sleep, mood, and concentration in cancer survivors. 172 participants will be assigned to real forest bathing, a virtual reality forest experience, guided imagery, or a waitlist. Each session lasts 30 m…
Sponsor: Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Talking it out: team approach may ease tough cancer decisions
Symptom relief OngoingThis study tests whether an extra meeting with a team of doctors, a palliative care specialist, and a psychologist can help patients with advanced cancer feel less torn about their next treatment. 62 adults with metastatic lung, breast, colon, ovarian, or prostate cancer who need…
Sponsor: Hospital Universitario San Ignacio • Aim: Symptom relief
Last updated Jun 26, 2026 16:52 UTC
-
Can tumor profiling help kids beat cancer? new study aims to find out
Knowledge-focused OngoingThis study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Sep 21, 2026 14:00 UTC
-
New study examines immunotherapy outcomes in american indian cancer patients
Knowledge-focused OngoingThis study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Can we predict who will benefit from immunotherapy? new study aims to find out.
Knowledge-focused OngoingThis study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
MD anderson study seeks to improve care for asian cancer patients
Knowledge-focused OngoingThis study aims to understand what helps or hinders a positive experience for Asian patients being treated for cancer at MD Anderson. Researchers will survey former patients and healthcare providers to identify key factors. The goal is to use these insights to improve care and su…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Could a frailty score predict which older cancer patients survive intensive care?
Knowledge-focused OngoingOlder adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Massive NCI study tracks thousands of cancer patients receiving standard care
Knowledge-focused By invitation onlyThis study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Massive cancer screening trial aims to cut deaths
Knowledge-focused OngoingThis study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New program aims to boost genetic testing in cancer families
Knowledge-focused OngoingThis study looks at whether a website and a genetic family navigator can help more relatives of people with hereditary cancer get genetic testing. About 205 participants will use the online hub and work with a navigator to learn about their cancer risk. The goal is to see if this…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
New study aims to predict cancer return in Low-Risk patients
Knowledge-focused OngoingThis study looks at whether molecular testing and lymph node mapping can help predict if low-risk endometrial cancer will return after surgery. About 518 patients with early-stage, low-grade cancer will be followed for two years. The goal is to improve follow-up care by identifyi…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused By invitation onlyThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Community cancer Centers' testing practices under review
Knowledge-focused CancelledThis study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Can we predict who recovers best from radical cancer surgery?
Knowledge-focused OngoingThis study follows women who have had pelvic exenteration—a surgery removing the lower colon, rectum, and bladder—for gynecologic cancers like cervical or endometrial cancer. Researchers want to see if factors like tumor size or surgery type affect complications, quality of life,…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 16, 2026 00:00 UTC
-
New web tool aims to help cancer patients make sense of their genes
Knowledge-focused OngoingThis study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
NIH launches biobank to unlock DNA secrets of Women's cancers
Knowledge-focused By invitation onlyThis study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Robots that feel: new study tests Touch-Sensitive surgery tools
Knowledge-focused OngoingThis study watches how force feedback instruments work during robot-assisted surgeries with the da Vinci 5 system. About 200 adults having hernia, colorectal, thoracic, gynecologic, or partial kidney removal surgery will take part. The goal is to see how these tools help surgeons…
Sponsor: Intuitive Surgical • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
Choice or fixed? study tests how to get better data from young cancer patients
Knowledge-focused OngoingThis study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…
Early phase 1 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New study: diet and exercise may boost sleep and reduce stress in cancer survivors
Knowledge-focused OngoingThis study is testing a 24-week program that combines nutrition counseling, exercise, sleep tips, and stress management for cancer survivors who are overweight. Researchers want to see if the program is practical and helpful for improving sleep quality, reducing stress, and boost…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
50,000 samples to unlock secrets of hereditary tumors
Knowledge-focused CancelledThis study will collect blood and tumor tissue from up to 50,000 adults with hereditary or genetic-linked cancers. Researchers will use these samples to create lab-grown tumor models, like mini-tumors, to study how these cancers work and test new treatments. The goal is to better…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
A digital guide aims to help latinx cancer patients navigate genomic testing decisions
Knowledge-focused OngoingResearchers are testing an online decision support tool called Gene PilotLX to see if it helps Latinx cancer patients make informed choices about tumor genomic testing. Tumor genomic testing looks for genetic changes in a tumor that might guide treatment or reveal hereditary risk…
Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Researchers dig into past data to uncover M7824's hidden side effects
Knowledge-focused OngoingThis study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
500 cancer Patients' records reviewed to tame immunotherapy side effects
Knowledge-focused OngoingThis study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
HPV Vaccine's Long-Term effects under the microscope in costa rica
Knowledge-focused OngoingThis study follows over 8,600 women in Costa Rica who received the HPV vaccine (types 16 and 18) years ago, plus unvaccinated controls, to see how well the vaccine protects over time. Researchers are checking for cervical lesions, immune markers, and any increase in infections fr…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Cancer treatment gets personal: MATCH trial tests Gene-Guided drugs
Knowledge-focused OngoingThis phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Why does cervical cancer persist despite prevention tools? a study seeks answers
Knowledge-focused OngoingResearchers are collecting detailed information from 524 women with cervical cancer across Latin America to understand why the disease remains common despite effective prevention tools. The study will document tumor types and cancer stages at diagnosis. The goal is to build a sol…
Sponsor: Latin American Cooperative Oncology Group • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
New program aims to bridge the trust gap between oncologists and latino patients
Knowledge-focused By invitation onlyThis study tests a program called HOLA that teaches oncologists special communication skills to build better relationships with their Latino patients who have advanced cancer. Researchers will compare how strong the bond is between doctors who take the training and those who don'…
Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Aug 29, 2026 00:00 UTC
-
AI helps doctors remember what matters most to cancer patients
Knowledge-focused OngoingThis study tests whether an AI tool can accurately summarize serious illness conversations between doctors and cancer patients. Researchers will send these summaries to doctors caring for hospitalized patients with advanced cancer. The goal is to see if the summaries are accurate…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Cancer kids show surprising strength: study reveals growth, not just trauma
Knowledge-focused OngoingThis study looks at how children with cancer and their parents handle the emotional challenges of the disease. Instead of focusing only on negative effects like posttraumatic stress, researchers also explore positive changes, such as personal growth. The study compares these fami…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
15-Year safety watch for cell therapy recipients
Knowledge-focused By invitation onlyThis study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …
Phase 1 • Sponsor: USWM CT, LLC • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Gut bacteria may hold key to safer cancer immunotherapy
Knowledge-focused OngoingThis study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Blood test clues could sharpen cervical cancer treatment
Knowledge-focused OngoingThis study looks at whether simple blood tests can help predict how aggressive cervical cancer might be. Researchers will measure inflammatory markers in blood samples from women with early-stage cervical cancer and compare them to tumor characteristics. The goal is to see if the…
Sponsor: University of Campania Luigi Vanvitelli • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Do blood thinners help or hurt when cancer meets a clot?
Knowledge-focused OngoingThis study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can natural remedies and cancer treatments mix safely? a new study investigates
Knowledge-focused OngoingThis study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…
Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Beyond BRCA: new gene panel could sharpen cancer risk prediction
Knowledge-focused OngoingThis study is investigating whether testing for a panel of 24 genes, in addition to the well-known BRCA1 and BRCA2 genes, can better estimate the risk of breast and ovarian cancer. Researchers will analyze genetic samples from people with a family history of these cancers, as wel…
Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Chatbot could help families of kids with cancer understand genetic risks
Knowledge-focused By invitation onlyThis study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
Knowledge-focused PausedThis study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…
Sponsor: Entia Ltd • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Cancer clinics study how to spot Patients' hidden struggles
Knowledge-focused By invitation onlyThis study looks at how community cancer clinics screen for health-related social needs, like help with housing, food, or transportation. Researchers will work with 144 clinic staff to understand what helps or hinders screening. The goal is to create custom plans to make screenin…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Tumor testing could unlock personalized cancer treatments
Knowledge-focused OngoingThis study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
New study tracks ovarian cancer care in real life
Knowledge-focused OngoingThis study follows 750 women with advanced ovarian cancer in Germany to see how they are treated in real-world settings. It focuses on the use of PARP inhibitor maintenance therapy after chemotherapy and how it affects outcomes and quality of life. The goal is to learn what works…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Island hopping for cancer care: first study maps Survivors' journeys across six caribbean nations
Knowledge-focused By invitation onlyThis study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…
Sponsor: Vaughan A. Lewis Institute for Research and Innovation • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Smartwatches for cancer survivors: a new way to track symptoms?
Knowledge-focused OngoingThis study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…
Sponsor: Laura Longshaw • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
New test could predict immunotherapy success from live tumor samples
Knowledge-focused OngoingThis observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…
Sponsor: Elephas • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Can coaching caregivers improve cancer Decision-Making?
Knowledge-focused OngoingThis study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a simple card keep cancer patients safer?
Knowledge-focused OngoingThis study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Massive 30-Year Women's health study reveals hidden disease links
Knowledge-focused OngoingThis long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Does surgery spread cervical cancer cells? new study investigates
Knowledge-focused OngoingThis study looks at whether surgery for early-stage cervical cancer causes tumor cells to enter the bloodstream, which might explain higher recurrence rates seen with certain surgical methods. Researchers will take blood samples from 20 women during their operation to detect circ…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Keytruda immune response trial aims to unlock cancer clues
Knowledge-focused OngoingThis phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Cancer patients get help planning families in new study
Knowledge-focused OngoingThis study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New web tool aims to help young cancer patients plan for family future
Knowledge-focused OngoingThis study tests a web-based tool called REFLECT, designed to help adolescent and young adult cancer patients learn about fertility and genetic risks for future children. Sixteen participants who have had cancer care at Moffitt Cancer Center will use the tool and rate how easy an…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Massive ovarian cancer database reveals treatment trends across france
Knowledge-focused PausedThis study collects information from over 13,000 women treated for ovarian cancer at 18 French cancer centers. Researchers will look at patient details, tumor types, and treatments given to see how care has evolved since 2011. The goal is to understand what treatments are used an…
Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Gene therapy safety check: 400 cancer patients monitored for years
Knowledge-focused By invitation onlyThis study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…
Sponsor: A2 Biotherapeutics Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Cancer imaging study pulled before starting
Knowledge-focused CancelledThis study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…
Early phase 1 • Sponsor: University of Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Massive cancer survival study launched in russia
Knowledge-focused OngoingThis study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…
Sponsor: N.N. Petrov National Medical Research Center of Oncology • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:33 UTC
-
One workout could boost cancer fighters?
Knowledge-focused OngoingThis study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …
Phase 2 • Sponsor: Universität Duisburg-Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Oxygen clues could unlock better cervical cancer treatment
Knowledge-focused OngoingThis study aims to find biological markers (biomarkers) that show which cervical cancers have low oxygen levels, making them harder to treat with standard radiation. About 30 patients with advanced cervical cancer will have special MRI scans and tumor biopsies before and during t…
Sponsor: University of Manchester • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New study tracks pelvic changes after radiation in women with pelvic cancer
Knowledge-focused OngoingThis study follows 72 women with pelvic cancers (anal, cervical, endometrial, rectal, vaginal, or vulvar) who are receiving radiation therapy. Researchers will use pelvic exams and surveys to measure changes in vaginal health, sexual function, and quality of life over two years. …
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Study questions best surgery for High-Risk endometrial cancer
Knowledge-focused OngoingThis study looks back at 700 patients with endometrial cancer to compare two surgical approaches: minimally invasive surgery (laparoscopy) and open surgery (laparotomy). The goal is to see which method is safer and leads to better long-term outcomes, especially for patients at hi…
Sponsor: Azienda USL Reggio Emilia - IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Patients claim cannabis stops tumor growth – scientists investigate
Knowledge-focused OngoingThis study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.
Sponsor: HealthPartners Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Electronic surveys tested for tracking radiation side effects in gynecologic cancer
Knowledge-focused OngoingThis study aims to see if it is practical to use electronic questionnaires to measure patient-reported symptoms before, during, and after radiation treatment for gynecologic cancer. About 100 English-speaking adults receiving radiation at UNC will participate. The main goal is to…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
New genetic panel could personalize cancer treatment
Knowledge-focused OngoingThis study enrolls 4,000 people with breast, ovarian, or colorectal cancer to test a comprehensive genetic panel. The panel looks for inherited cancer risks and tumor mutations that may affect drug sensitivity. Researchers aim to validate these genetic findings to potentially gui…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Ovarian cancer breakthrough? tumor slices could reveal best drug for each patient
Knowledge-focused OngoingThis study tests whether thin slices of ovarian tumors, kept alive in the lab, can predict how a patient will respond to chemotherapy. Researchers will take tumor samples from 48 women with advanced ovarian cancer during surgery. They will then expose the slices to different drug…
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Smartwatches track cancer symptoms at home
Knowledge-focused By invitation onlyThis study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Pregnancy DNA test may spot cancer in Moms-to-Be
Knowledge-focused By invitation onlyThis study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Lifestyle coaching aims to boost activity in cancer survivors
Knowledge-focused OngoingThis study tests whether personalized telehealth coaching can help young adult cancer survivors become more physically active and improve their diet. Researchers are enrolling 374 survivors aged 18-54 who are not very active. Participants receive one-on-one sessions with a clinic…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study aims to improve cancer care for seniors
Knowledge-focused By invitation onlyThis study looks at whether training and support can help cancer clinics give special check-ups (called geriatric assessments) to patients aged 65 and older who are starting a new cancer treatment. These check-ups help find and address health issues, support needs, and daily life…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New Full-Body PET scanner promises faster scans, less radiation
Knowledge-focused OngoingThis study compares a new total body PET scanner (Omni TB) with conventional PET in 25 adult cancer patients. The new scanner can image the whole body at once with higher sensitivity, potentially allowing shorter scan times and lower radiation doses. Researchers will assess wheth…
Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Tracking childhood cancer survivors for decades to improve their future health
Knowledge-focused OngoingThis long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Scientists hunt for genetic markers in ovarian, uterine, and cervical cancers
Knowledge-focused OngoingThis study is collecting blood and tumor samples from 300 people suspected of having ovarian, endometrial, or cervical cancer. Researchers will analyze the samples to find genetic changes that might predict how the cancer behaves. The goal is to better understand these cancers, n…
Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Skin sensor could alert doctors to rising pain in cancer and COPD patients
Knowledge-focused OngoingThis study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …
Sponsor: Copenhagen University Hospital, Hvidovre • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Study probes Patients' minds, not their tumors
Knowledge-focused OngoingThis study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…
Sponsor: Tomas Bata Hospital, Czech Republic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Lab test could match cancer patients to the right drugs
Knowledge-focused OngoingThis study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…
Sponsor: China Medical University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Racial gap in cancer treatment? new study investigates immunotherapy outcomes
Knowledge-focused OngoingThis study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…
Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New study aims to predict and prevent dangerous drug reactions
Knowledge-focused OngoingThis study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal i…
Sponsor: Direzione centrale salute, politiche sociali e disabilità • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New MRI-Guided radiotherapy machine put to the test
Knowledge-focused OngoingThis study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
MRI-Guided radiation: a sharper weapon against cancer?
Knowledge-focused OngoingThis study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can we track brain health in older cancer patients?
Knowledge-focused OngoingThis study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …
Sponsor: Our Lady's Hospice and Care Services • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
New online tool aims to clear up confusion around cancer screening
Knowledge-focused CancelledThis study aimed to create a web-based decision aid for people invited to cancer screening in Sweden. The tool would provide clear information about the benefits and harms of screening, helping individuals decide based on knowledge rather than fear. The study was withdrawn before…
Sponsor: Karolinska Institutet • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
7,000 tumor samples analyzed to uncover Cancer's hidden support system
Knowledge-focused OngoingThis study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
New dosing method for Kids' cancer drug aims to reduce side effects
Knowledge-focused OngoingThis study looks at a new method for giving the cancer drug vincristine to infants and young children. The goal is to see if this new way of calculating the dose leads to similar drug levels in the blood as the standard method used in older children. About 83 children up to 12 ye…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Telehealth under the microscope: did virtual cancer care hold up during COVID?
Knowledge-focused By invitation onlyThis study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Asian hospitals join forces to personalize endometrial cancer care
Knowledge-focused OngoingThis study collects information from about 300 endometrial cancer patients across Asia to see how doctors use cancer cell features to choose treatments. The goal is to learn which patients need stronger therapy and which can avoid extra side effects. No new treatments are tested—…
Sponsor: Tata Memorial Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can a short video help cancer patients get better palliative care?
Knowledge-focused OngoingThis study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…
Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Italy launches massive genetic database to match cancer patients with better treatments
Knowledge-focused OngoingThis observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…
Sponsor: Federation of Italian Cooperative Oncology Groups • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Jail-Release program boosts Women's cancer and STD knowledge
Knowledge-focused OngoingThis study tests a program called the Sexual Health Empowerment (SHE) Project for women who are about to leave jail. The goal is to improve their understanding of cervical cancer, breast cancer, contraception, and sexually transmitted diseases. About 279 women will take part, and…
Sponsor: University of Kansas Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
New study aims to ease life after ovarian and endometrial cancer
Knowledge-focused OngoingThis study tests a personalized post-cancer care plan for women who have finished treatment for ovarian or endometrial cancer. About 99 participants will receive a day of support care and a tailored plan to address their needs. The goal is to see if this approach improves their l…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Kenya's Mother-Daughter program aims to slash cervical cancer deaths
Knowledge-focused OngoingThis study enrolls 2,300 Kenyan women and girls to improve cervical cancer prevention. Women provide self-collected swabs for HPV testing and undergo standard visual screening. The goal is to see if self-testing is as good as or better than current methods, and to understand what…
Sponsor: Indiana University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Withdrawn study sought to understand when lymphoma and cancer strike together
Knowledge-focused CancelledThis study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Pandemic delays led to fewer cancer diagnoses, study of 438,000 cases shows
Knowledge-focused OngoingThis study looks at how the COVID-19 pandemic changed the number of new cancer cases in Bavaria, Germany. Researchers analyzed data from 438,000 adults diagnosed with cancer between 2018 and 2023 to see if certain regions or cancer types were more affected. The goal is to underst…
Sponsor: Bavarian Cancer Registry • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Young cancer survivors face hidden financial toll
Knowledge-focused By invitation onlyThis study looks at financial problems (called 'financial toxicity') in young adults aged 18-39 who have finished cancer treatment. Researchers will survey 300 participants to measure money stress during and after therapy, and find out what factors make it worse. The goal is to l…
Sponsor: University Medical Center Goettingen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Can community navigation cut cancer delays? botswana trial aims to find out
Knowledge-focused OngoingThis study tests a program called Potlako+ that combines community education, support for healthcare providers, and patient navigation to help people with cancer symptoms get diagnosed and treated faster. About 874 participants in Botswana will be split into two groups: one recei…
Phase 2 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Can laughter yoga and art therapy ease cancer distress?
Knowledge-focused By invitation onlyThis study looks at how mind-body therapies—like mindfulness, laughter yoga, and art therapy—affect the quality of life and emotional distress of 150 cancer patients. Participants will fill out questionnaires before and after an 8-week program. The goal is to see if these therapi…
Sponsor: La Tour Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Stem cells may unlock mystery of chemo-related heart damage
Knowledge-focused OngoingThis study uses stem cells made from patients' own cells to understand why some people develop severe heart or lung side effects from certain chemotherapy drugs. Researchers will compare cells from patients who had extreme toxicity to those who did not. The goal is to uncover the…
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
New online tool aims to help older cancer patients get better treatment plans
Knowledge-focused OngoingThis study is testing an online questionnaire called CHAMP that older adults with cancer can fill out before their doctor's visit. The tool asks about daily function, memory, mood, and support to help doctors tailor cancer treatment. Researchers want to see if the tool is easy to…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Could your genes raise your lung cancer risk? new study investigates
Knowledge-focused OngoingThis study looks at whether certain inherited gene changes (EGFR mutations) increase the risk of lung cancer, especially in people who never smoked. Researchers collect saliva from cancer patients with a specific tumor mutation (T790M) to find these inherited changes. They also o…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Can community outreach boost cancer screening in kenya? new study aims to find out
Knowledge-focused OngoingThis study tests whether community education and support can increase the number of women in Kenya who get screened for breast and cervical cancer. Researchers will enroll 5,400 women aged 30-55 and track how many complete recommended screenings and follow-up care. The goal is to…
Sponsor: Implenomics • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Transgender men and cervical cancer screening: what's holding them back?
Knowledge-focused OngoingThis study uses a survey to understand why transgender men (people assigned female at birth who identify as male) in France may not get screened for cervical cancer. Researchers will ask 300 participants aged 25–65 about their screening history and what helps or hinders them. The…
Sponsor: Centre Hospitalier Universitaire de Nīmes • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Gut bacteria could be key to better cancer immunotherapy
Knowledge-focused OngoingThis study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New study tracks ovarian health after chemo in young women
Knowledge-focused OngoingThis study follows 196 women aged 11-35 who are receiving chemotherapy for cancer. Researchers measure hormone levels and ovarian follicles before, during, and after treatment to see how the ovaries are affected. The goal is to better understand the risk of early menopause and fe…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Cancer Patients' vaccine response under microscope
Knowledge-focused OngoingThis study looks at how well cancer patients respond to common vaccines like flu, COVID-19, and shingles. Researchers will measure antibody levels before and after vaccination in 250 adults with cancer. The goal is to understand immune responses in this group, not to test a new t…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
New study explores how genetic risk info shapes ovarian cancer decisions
Knowledge-focused OngoingThis study interviews 24 women with BRCA1 or BRCA2 mutations to learn how they might use polygenic risk scores and multi-cancer early detection tests when deciding about cancer screening or risk-reducing surgery. The goal is to better understand patient attitudes, not to test a t…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Blood test could replace painful biopsies for cancer patients
Knowledge-focused OngoingThis study looks at whether a blood test (liquid biopsy) can find cancer mutations as well as the standard tissue biopsy. Researchers will compare the two methods in 1,500 advanced cancer patients to see if the blood test helps doctors choose better treatments and saves money. Th…
Sponsor: British Columbia Cancer Agency • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
Surviving rare ovarian cancer: what comes next? new study investigates Long-Term fatigue and health
Knowledge-focused OngoingThis study looks at women who have recovered from rare ovarian cancers (germ cell or sex cord-stromal tumors) to understand how the disease and chemotherapy affect their lives years later. Researchers will use questionnaires to measure chronic fatigue, quality of life, and other …
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:51 UTC
-
New study tests tools to help families share cancer genetic results
Knowledge-focused OngoingThe IMPACT Study is testing two online tools—GeneSHARE and LivingLabReport—to help people with inherited cancer gene variants share their results with family members and follow cancer screening guidelines. The study involves 720 adults who have a genetic variant linked to cancers…
Sponsor: Vanderbilt-Ingram Cancer Center • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:58 UTC
-
Blood test may replace tissue biopsies for ovarian cancer monitoring
Knowledge-focused OngoingThis study looks at whether a simple blood test (liquid biopsy) can track how ovarian cancer changes over time, instead of taking multiple tissue samples. Twenty newly diagnosed patients will give blood and tissue samples during their treatment for up to two years. The goal is to…
Sponsor: Institut de Cancérologie de Lorraine • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:28 UTC
-
New algorithm aims to catch ovarian damage early in young cancer survivors
Knowledge-focused CancelledThis study was designed to see if a new monitoring algorithm could detect early signs of ovarian damage in women and girls who had cancer treatment. Researchers planned to compare a group using the new algorithm with a group that received standard care. However, the study was wit…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:42 UTC
-
Simple blood test may reveal how far cancer has spread
Knowledge-focused OngoingThis study is checking if two substances in the blood, called IGF-1 and IGF-1Ec, are linked to how much cancer is in the body. Researchers will measure these levels in 100 adults with solid tumors and compare them to tumor size, stage, and spread. The goal is to see if these mark…
Sponsor: Çanakkale Onsekiz Mart University • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:18 UTC